Search Results - "Absmaier, Magdalena"
-
1
Fetal Tissue-Derived Mast Cells (MC) as Experimental Surrogate for In Vivo Connective Tissue MC
Published in Cells (Basel, Switzerland) (08-03-2022)“…Bone-marrow-derived mast cells are matured from bone marrow cells in medium containing 20% fetal calf serum (FCS), interleukin (IL)-3 and stem-cell factor…”
Get full text
Journal Article -
2
Allergic myocardial infarction (Kounis syndrome) after cefuroxime with side-chain cross-reactivity
Published in The journal of allergy and clinical immunology in practice (Cambridge, MA) (01-09-2018)“…Generalized vasodilation and increased vascular permeability lead to a decrease in circulating blood volume of up to one-third, causing coronary hypoperfusion…”
Get full text
Journal Article -
3
PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients
Published in International journal of oncology (01-03-2018)“…Triple-negative breast cancer (TNBC) constitutes a heterogeneous breast cancer subgroup with poor prognosis; survival rates are likely to be lower with TNBC…”
Get full text
Journal Article -
4
The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges
Published in Disease markers (01-01-2017)“…High-risk breast cancer comprises distinct tumor entities such as triple-negative breast cancer (TNBC) which is characterized by lack of estrogen (ER) and…”
Get full text
Journal Article -
5
Characterization of the honeybee venom proteins C1q-like protein and PVF1 and their allergenic potential
Published in Toxicon (Oxford) (01-08-2018)“…Honeybee (Apis mellifera) venom (HBV) represents an ideal model to study the role of particular venom components in allergic reactions in sensitized…”
Get full text
Journal Article -
6
T-Cell Subtypes and Immune Signatures in Cutaneous Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy
Published in Cancers (20-03-2024)“…Immune checkpoint inhibition (ICI) improves outcomes in melanoma patients, but associated T-cell activation frequently leads to immune-related cutaneous…”
Get full text
Journal Article -
7